97
Participants
Start Date
April 27, 2016
Primary Completion Date
March 9, 2021
Study Completion Date
March 9, 2021
PF-06817024
Subjects will be given one dose of PF-06817024 intravenously
Placebo for PF-06817024
Subjects will be given one dose of placebo for PF-06817024 intravenously
PF-06817024
Subjects will be given one dose of PF-06817024 subcutaneously
Placebo for PF-06817024
Subjects will be given one dose of placebo for PF-06817024 subcutaneously
PF-06817024
Subjects will be given two doses of PF-06817024 intravenously
Placebo for PF-06817024
Subjects will be given two doses of PF-06817024 intravenously
PF-06817024
Subjects will be given 2 doses intravenously
Placebo for PF-06817024
Subjects will be given 2 doses intravenously
PF-06817024
Subjects will be given doses of PF-06817024 intravenously
Placebo for PF-06817024
Subjects will be given doses of Placebo intravenously
Virginia Clinical Research, Inc., Norfolk
Carolina Phase 1 Research, LLC, Raleigh
ForCare Clinical Research, Tampa
The Indiana Clinical Trials Center, Plainfield
Dawes Fretzin Clinical Research Group, LLC, Indianapolis
Dawes Fretzin Dermatology Group, LLC, Indianapolis
Prism Research, LLC, Saint Paul
Clinical Research Institute, Inc., Minneapolis
Ear, Nose & Throat Specialty Care of Minnesota, P.A., Minneapolis
Academic Dermatology, Edina
Health Concepts, Rapid City
Vital Prospects Clinical Research Institute, PC, Tulsa
Lee Medical Associates, PA, San Antonio
Progressive Clinical Research, PA, San Antonio
UC Davis Dermatology, Sacramento
UC Davis CTSC Clinical Research Center, Sacramento
UC Davis Health, Sacramento
New Haven Clinical Research Unit, New Haven
Dermatology Physicians of Connecticut, Shelton
Hassman Research Institute, Berlin
Lead Sponsor
Pfizer
INDUSTRY